43 related articles for article (PubMed ID: 15192923)
1. An RCT into calculating insulin start dose in type 2 diabetes.
Jarvis J; Burden A; Burden ML
Nurs Times; 2004 May 25-31; 100(21):40-4. PubMed ID: 15192923
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of glargine group-start sessions in patients with type 2 diabetes as a strategy to deliver the service.
Tahrani AA; Digwood S; Lee C; Moulik P
Int J Clin Pract; 2007 Feb; 61(2):329-35. PubMed ID: 17263721
[TBL] [Abstract][Full Text] [Related]
3. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
[TBL] [Abstract][Full Text] [Related]
4. Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial.
Douek IF; Allen SE; Ewings P; Gale EA; Bingley PJ;
Diabet Med; 2005 May; 22(5):634-40. PubMed ID: 15842521
[TBL] [Abstract][Full Text] [Related]
5. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
[TBL] [Abstract][Full Text] [Related]
6. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
Clements MR; Tits J; Kinsley BT; Råstam J; Friberg HH; Ligthelm RJ
Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
[TBL] [Abstract][Full Text] [Related]
7. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
[TBL] [Abstract][Full Text] [Related]
8. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
Ligthelm RJ; Mouritzen U; Lynggaard H; Landin-Olsson M; Fox C; le Devehat C; Romero E; Liebl A
Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
[TBL] [Abstract][Full Text] [Related]
9. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
Yang W; Ji Q; Zhu D; Yang J; Chen L; Liu Z; Yu D; Yan L
Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
[TBL] [Abstract][Full Text] [Related]
10. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.
Valensi P; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Wenying Y;
Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170
[TBL] [Abstract][Full Text] [Related]
11. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
Rowe R; Cowx M; Poole C; McEwan P; Morgan C; Walker M
Curr Med Res Opin; 2005 Nov; 21(11):1885-90. PubMed ID: 16307710
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
Dornhorst A; Lüddeke HJ; Sreenan S; Koenen C; Hansen JB; Tsur A; Landstedt-Hallin L
Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628
[TBL] [Abstract][Full Text] [Related]
13. An intensified lifestyle intervention programme may be superior to insulin treatment in poorly controlled Type 2 diabetic patients on oral hypoglycaemic agents: results of a feasibility study.
Aas AM; Bergstad I; Thorsby PM; Johannesen O; Solberg M; Birkeland KI
Diabet Med; 2005 Mar; 22(3):316-22. PubMed ID: 15717881
[TBL] [Abstract][Full Text] [Related]
14. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
Meneghini L; Koenen C; Weng W; Selam JL
Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
[TBL] [Abstract][Full Text] [Related]
15. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
Hausmann M; Dellweg S; Osborn C; Heinemann L; Buchwald A; Rosskamp R; Genova P; Heise T
Diabetes Obes Metab; 2006 Sep; 8(5):574-80. PubMed ID: 16918593
[TBL] [Abstract][Full Text] [Related]
16. Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine.
Bradley C; Gilbride CJ
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():50-65. PubMed ID: 18577157
[TBL] [Abstract][Full Text] [Related]
17. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
18. Type 2 diabetes mellitus--guidelines for initiating insulin therapy.
Yeap BB
Aust Fam Physician; 2007 Jul; 36(7):549-53. PubMed ID: 17619673
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of inhaled insulin (AERx iDMS) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1-year data from a randomized, parallel group trial.
Moses RG; Bartley P; Lunt H; O'Brien RC; Donnelly T; Gall MA; Vesterager A; Wollmer P; Roberts A
Diabet Med; 2009 Mar; 26(3):260-7. PubMed ID: 19317821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
